Indeed, the downregulation of TRPV2 observed in MS patients suggests that TRPV2 may be playing a role, either as a cause or consequence, in this disease, and that promoting its specific activation/inhibition could be an interesting therapeutic target to be explored. The gene discussed is TRPV2; the disease is myeloid sarcoma.